Cytiva, a Danaher company and global life sciences leader, has partnered with Veeda Lifesciences to launch a dedicated Host Cell Protein (HCP) Services Center in Bengaluru. The new center will help biopharma companies reduce development risks and meet strict regulatory standards for biologics and biosimilars.
Why This Center Matters for Biologics Developers?
Host cell proteins are tiny impurities that can trigger toxicity, immune reactions, or stability issues in biologics. Detecting and quantifying them early is essential.
The new HCP center aims to solve this by offering:
- High-quality impurity analysis
- Regulatory-ready HCP testing
- Faster and more accurate analytical workflows
- Support for biologics, biosimilars, vaccines, and recombinant proteins
Bringing Analytical Strength Under One Roof
Located within Veeda’s facility and powered by Cytiva’s technology, the center will operate as a full analytical hub for:
- Biopharma manufacturers
- Research institutions
- Academic labs
Using advanced multi-attribute DIGE techniques, the lab will generate reliable data for regulatory submissions and quality assessments.
Key services include:
- HCP coverage analysis
- Characterization assays
- Quantification assays
- Combined ELISA and mass spectrometry workflows
These capabilities will help companies ensure process effectiveness and protect patient safety.
Leadership Insights
Dr. Mahesh Bhalgat, Group CEO, Veeda Lifesciences, highlighted the impact:
“Analytical data drives product approvals. This partnership strengthens the foundation of biosimilar regulatory pathways.”
Manoj Kumar R. Panicker, General Manager, South Asia, Cytiva, added:
“This center shows what is possible when science and industry unite to advance biopharma innovation.”
A Boost for India’s Growing Bioeconomy
According to Cytiva’s 2025 Biopharma Index, the industry is demanding better analytical and digital tools for regulatory assurance and process control. The new center aligns perfectly with this trend.
As India moves toward a USD 300 billion bioeconomy by 2030, initiatives like this reinforce the country's position as a global biologics and biosimilars powerhouse.
